CN107922609B - 基于阳离子粘酸聚合物的递送系统 - Google Patents

基于阳离子粘酸聚合物的递送系统 Download PDF

Info

Publication number
CN107922609B
CN107922609B CN201680050424.6A CN201680050424A CN107922609B CN 107922609 B CN107922609 B CN 107922609B CN 201680050424 A CN201680050424 A CN 201680050424A CN 107922609 B CN107922609 B CN 107922609B
Authority
CN
China
Prior art keywords
polymer
cmap
nanoparticle
independently
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680050424.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107922609A (zh
Inventor
马克·E·戴维斯
多罗西·潘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology
Original Assignee
California Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology filed Critical California Institute of Technology
Priority to CN202010303591.5A priority Critical patent/CN111643479B/zh
Publication of CN107922609A publication Critical patent/CN107922609A/zh
Application granted granted Critical
Publication of CN107922609B publication Critical patent/CN107922609B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/40—Polyamides containing oxygen in the form of ether groups
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G79/00—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
    • C08G79/08—Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing boron
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Polyethers (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
CN201680050424.6A 2015-07-01 2016-06-13 基于阳离子粘酸聚合物的递送系统 Active CN107922609B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010303591.5A CN111643479B (zh) 2015-07-01 2016-06-13 基于阳离子粘酸聚合物的递送系统

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187366P 2015-07-01 2015-07-01
US62/187,366 2015-07-01
PCT/US2016/037166 WO2017003668A1 (en) 2015-07-01 2016-06-13 Cationic mucic acid polymer-based delivery systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010303591.5A Division CN111643479B (zh) 2015-07-01 2016-06-13 基于阳离子粘酸聚合物的递送系统

Publications (2)

Publication Number Publication Date
CN107922609A CN107922609A (zh) 2018-04-17
CN107922609B true CN107922609B (zh) 2020-04-24

Family

ID=57609004

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680050424.6A Active CN107922609B (zh) 2015-07-01 2016-06-13 基于阳离子粘酸聚合物的递送系统
CN202010303591.5A Active CN111643479B (zh) 2015-07-01 2016-06-13 基于阳离子粘酸聚合物的递送系统

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010303591.5A Active CN111643479B (zh) 2015-07-01 2016-06-13 基于阳离子粘酸聚合物的递送系统

Country Status (6)

Country Link
US (4) US10287401B2 (cg-RX-API-DMAC7.html)
EP (2) EP3317323B1 (cg-RX-API-DMAC7.html)
JP (4) JP6914860B2 (cg-RX-API-DMAC7.html)
CN (2) CN107922609B (cg-RX-API-DMAC7.html)
ES (2) ES2980216T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017003668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP3317323B1 (en) 2015-07-01 2021-05-26 California Institute of Technology Cationic mucic acid polymer-based delivery systems
US20190381188A1 (en) * 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
CN113905786A (zh) * 2019-05-29 2022-01-07 国立大学法人东京工业大学 复合物、药物、癌症治疗剂、试剂盒和缀合物
WO2021113643A2 (en) 2019-12-04 2021-06-10 Dantari, Inc. Methods and compositions for synthesis of therapeutic nanoparticles
JP7343874B2 (ja) * 2019-12-26 2023-09-13 株式会社島津製作所 データ処理方法及びデータ処理装置
EP4691490A1 (en) 2023-03-31 2026-02-11 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
ES2064101T3 (es) 1990-04-02 1995-01-16 Pfizer Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
JPH06503095A (ja) 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5936079A (en) 1992-04-06 1999-08-10 Alton Ochsner Medical Foundation Oligonucleotide which binds to a chromosomal binding site for p53 protein
EP0654024A1 (en) 1992-08-06 1995-05-24 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US6610832B1 (en) 1995-03-23 2003-08-26 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5693631A (en) 1995-05-30 1997-12-02 Buckman Laboratories International, Inc. Potentiation of the microbicide 2-(thiocyanomethylthio) benzothiazole using an N-alkyl heterocyclic compound
US6034081A (en) 1995-05-30 2000-03-07 Buckman Laboratories International Inc Potentiation of biocide activity using an N-alkyl heterocyclic compound
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
US5596878A (en) 1995-06-26 1997-01-28 Thermo King Corporation Methods and apparatus for operating a refrigeration unit
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
FR2749853B1 (fr) 1996-06-12 1998-10-16 Rhone Poulenc Chimie Formulation amelioree a base d'un compose hydroxyle et d'un compose amphiphile complexant utilisable notamment pour modifier les proprietes rheologiques d'emulsions
AU3739697A (en) 1996-07-09 1998-02-02 Johns Hopkins University, The Gene delivery system
AR007855A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US5948878A (en) 1997-04-15 1999-09-07 Burgess; Stephen W. Cationic polymers for nucleic acid transfection and bioactive agent delivery
JP4503825B2 (ja) 1997-08-27 2010-07-14 カリフォルニア インスティテュート オブ テクノロジー 生物学的組織において癒着の形成を防止するための方法および組成物
US6225346B1 (en) 1997-10-24 2001-05-01 Sugen, Inc. Tyrphostin like compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US7091192B1 (en) 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
WO2000010007A2 (en) 1998-08-17 2000-02-24 California Institute Of Technology Devices and methods for analysis of non-ionic solutes
DE69921158T2 (de) 1998-08-27 2006-01-12 Eidgenössische Technische Hochschule Zürich Gele und mehrschichtige oberflächenstrukturen aus boronsäurehaltigen polymeren
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
PE20011178A1 (es) 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
CN1437594A (zh) 2000-06-22 2003-08-20 辉瑞产品公司 用于治疗异常细胞生长的取代的双环衍生物
CA2413134C (en) 2000-06-30 2010-05-11 Glaxo Group Limited Quinazoline ditosylate salt compounds
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7041280B2 (en) 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
JP2005511761A (ja) 2001-07-10 2005-04-28 ノース・キャロライナ・ステイト・ユニヴァーシティ ナノ粒子送達ビヒクル
IL160010A0 (en) 2001-07-23 2004-06-20 Univ Ramot Methods and compositions for treating fungal infections
US6737504B2 (en) 2001-07-30 2004-05-18 California Institute Of Technology Synthesis of substituted poly(aniline)s
CN1628126A (zh) 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
EP1439178A4 (en) 2001-10-05 2005-11-16 Takeda Pharmaceutical Heterocyclic compounds, oxazole derivatives, process for their preparation and their use
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
IL161908A0 (en) 2001-12-12 2005-11-20 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
CN1608062A (zh) 2001-12-12 2005-04-20 辉瑞产品公司 E-2-甲氧基-n-(3-{4-[3-甲基-4-(6-甲基-吡啶-3-基氧基) -苯氨基]-喹唑啉-6基}-烯丙基)-乙酰胺的盐,其制备和抗癌用途
WO2003053446A1 (en) 2001-12-19 2003-07-03 Smithkline Beecham Corporation Thienopyrimidine compounds as protein tyrosine kinase inhibitors
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7094427B2 (en) 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
AU2003241898A1 (en) 2002-06-03 2003-12-19 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
AU2003291567A1 (en) 2002-11-19 2004-06-15 Genzyme Corporation Polymeric boronic acid derivatives as lipase inhibitors
AU2003298749A1 (en) 2002-11-26 2004-06-18 Seacoast Neuroscience, Inc. Buoyant polymer particles delivering therapeutic agents
CN101153042A (zh) 2003-01-29 2008-04-02 武田药品工业株式会社 噻吩并嘧啶化合物及其用途
JP2005119255A (ja) 2003-10-17 2005-05-12 San Quest:Kk 携帯電話画像取り込み機能付き名刺印刷装置
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
US7399645B2 (en) 2004-05-12 2008-07-15 Applera Corporation Constrained cis-diol-borate bioconjugation system
CN101974125B (zh) 2004-07-30 2013-09-18 巴斯夫欧洲公司 聚合物硼酸衍生物及其在造纸中的用途
US7413173B2 (en) 2004-09-10 2008-08-19 Ric Investments, Llc Molded water chamber base plate for use in a humidifier and ventilator assembly
WO2006044275A2 (en) 2004-10-12 2006-04-27 Luminex Corporation Methods for altering surface characteristics of microspheres
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
PL1866414T3 (pl) 2005-03-31 2012-10-31 Calando Pharmaceuticals Inc Inhibitory podjednostki 2 reduktazy rybonukleotydowej i ich zastosowania
EP1893241A2 (en) 2005-04-28 2008-03-05 Ventana Medical Systems, Inc. Fluorescent nanoparticles conjugated to antibodies via a peg linker
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
JP2009508936A (ja) 2005-09-20 2009-03-05 イッサム リサーチ ディベロップメント カンパニー 活性物質の標的化送達用ナノ粒子
US7988988B2 (en) 2005-11-21 2011-08-02 Bausch & Lomb Incorporated Contact lenses with mucin affinity
EP2046266A4 (en) 2006-07-21 2009-11-04 Massachusetts Inst Technology ENDMODICIFIED POLY (BETA AMINO ESTER) AND ITS USE
BRPI0716046A2 (pt) 2006-08-17 2013-09-17 Novartis Ag composiÇÕes de nanopartÍcula.
BRPI0717545A2 (pt) 2006-09-29 2013-10-22 Gezyme Corp Composição farmacêutica, método para tratar uma doença, polímero de amida, rede de polímero, e, método para preparar um polímero de amida
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
WO2009036022A1 (en) 2007-09-10 2009-03-19 Board Of Regents, The University Of Texas System Enhancement of polysaccharide-mediated nucleic acid delivery
NZ602302A (en) 2007-12-28 2014-04-30 Impax Laboratories Inc Controlled release formulations of levodopa and uses thereof
US20100029545A1 (en) 2008-08-04 2010-02-04 Sumerlin Brent S Boronic acid-containing block copolymers for controlled drug delivery
ES2915692T3 (es) 2008-08-13 2022-06-24 California Inst Of Techn Nanopartículas portadoras y composiciones, métodos y sistemas relacionados
US8367166B2 (en) 2008-10-31 2013-02-05 Chevron U.S.A. Inc. Synthesis of higher diamondoids
CA2759098A1 (en) 2009-04-14 2010-10-21 Smith Holdings, Llc Methods and compositions for the treatment of medical conditions involving cellular programming
WO2010138193A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
FR2946476B1 (fr) 2009-06-05 2014-03-21 Aeg Power Solutions Bv Convertisseur continu-continu a regulation double alternance
US20100330686A1 (en) 2009-06-29 2010-12-30 Seung Bum Park Nanosensor for sugar detection
CN102906127A (zh) 2009-11-06 2013-01-30 华盛顿大学商业中心 来自两性离子聚合物的自组装颗粒以及相关的方法
WO2011072133A1 (en) 2009-12-09 2011-06-16 William Marsh Rice University Therapeutic compositions and methods for delivery of active agents cleavably linked to nanoparticles
WO2011097384A2 (en) 2010-02-04 2011-08-11 Board Of Regents, The University Of Texas System Tumor targeted delivery of immunomodulators by nanoplymers
US20130157926A1 (en) 2010-06-18 2013-06-20 Johannes Franciscus Joseph Engbersen Boronated polymers
US20120225129A1 (en) 2010-08-20 2012-09-06 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
US20120148488A1 (en) 2010-12-10 2012-06-14 California Institute Of Technology Targeting Kidney Mesangium With Nanoparticles of Defined Diameter
EP2707419B1 (en) 2011-05-13 2019-08-14 The Regents of The University of California Reversibly crosslinked micelle systems
DE102012017025B4 (de) 2012-08-28 2018-05-30 Kennametal Inc. Werkzeughalter für einen Schneideinsatz und Baugruppe mit einem solchen Werkzeughalter
GB201220474D0 (en) 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
EP2961788B1 (en) * 2013-03-01 2019-05-08 California Institute of Technology Nanoparticles stabilized with nitrophenylboronic acid compositions
US9132097B2 (en) 2013-03-01 2015-09-15 California Institute Of Technology Nanoparticles stabilized with nitrophenylboronic acid compositions
ES2986545T3 (es) 2013-03-01 2024-11-11 California Inst Of Techn Nanopartículas dirigidas
US9468681B2 (en) * 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
CA3166758A1 (en) 2013-05-14 2014-11-20 California Institute Of Technology Method of delivering therapeutics and imaging agents by nanoparticles that cross the blood brain barrier
WO2016037166A1 (en) 2014-09-07 2016-03-10 Yu Zhang Novel anti-oxidant compositions and methods of delivery
EP3317323B1 (en) 2015-07-01 2021-05-26 California Institute of Technology Cationic mucic acid polymer-based delivery systems

Also Published As

Publication number Publication date
EP3317323B1 (en) 2021-05-26
US20200283582A1 (en) 2020-09-10
WO2017003668A1 (en) 2017-01-05
EP3317323A4 (en) 2019-05-29
JP2022191285A (ja) 2022-12-27
US10717825B2 (en) 2020-07-21
CN107922609A (zh) 2018-04-17
ES2980216T3 (es) 2024-09-30
JP7708728B2 (ja) 2025-07-15
US20170002151A1 (en) 2017-01-05
US20210261739A1 (en) 2021-08-26
EP3795609B1 (en) 2024-04-03
JP2025100542A (ja) 2025-07-03
CN111643479B (zh) 2023-10-27
CN111643479A (zh) 2020-09-11
ES2882255T3 (es) 2021-12-01
US10287401B2 (en) 2019-05-14
US11041050B2 (en) 2021-06-22
US20190202995A1 (en) 2019-07-04
EP3317323A1 (en) 2018-05-09
JP2021181568A (ja) 2021-11-25
JP7150945B2 (ja) 2022-10-11
JP2018525462A (ja) 2018-09-06
EP3795609A1 (en) 2021-03-24
JP6914860B2 (ja) 2021-08-04

Similar Documents

Publication Publication Date Title
JP7708728B2 (ja) カチオン性粘液酸ポリマー系デリバリーシステム
Chang et al. Synthesis and characterization of DOX-conjugated dendrimer-modified magnetic iron oxide conjugates for magnetic resonance imaging, targeting, and drug delivery
KR101444274B1 (ko) 약제복합체용 블록 공중합체 및 의약조성물
JP5848127B2 (ja) 担体ナノ粒子ならびに関連する組成物、方法およびシステム
JP7046321B2 (ja) 修飾されたスチレン-無水マレイン酸共重合体及びその使用
CN113754793B (zh) 一种苯硼酸枝接的壳寡糖衍生物及其制备方法和应用
AU2007350282A1 (en) Dendrimers and methods of making and using thereof
Nie et al. In vitro and in vivo evaluation of stimuli-responsive vesicle from PEGylated hyperbranched PAMAM-doxorubicin conjugate for gastric cancer therapy
CN102526756A (zh) 阿霉素复合物、胶束及胶束的制备方法
CN110755633B (zh) 一种双pH敏感负载化疗药物柔红霉素的纳米传递系统的制备方法
WO2011065916A1 (en) Crosslinking branched molecule through thiol-disulfide exchange to form hydrogel
CN111743861B (zh) 靶向三阴性乳腺癌的低氧响应手性药物胶束及其制备方法
CN115957344B (zh) 一种共靶向肿瘤细胞和m2型巨噬细胞的载体和纳米递药系统及其制备方法
Zhao et al. Self-assembled thermosensitive nanoparticles based on oligoethylene glycol dendron conjugated doxorubicin: preparation, and efficient delivery of free doxorubicin
JP7739406B2 (ja) 含ハロゲン部位を有するポリマーおよび該ポリマーを用いた医薬組成物
CN114573729A (zh) 一种线粒体靶向的糖原衍生物药物载体及其在药物递送领域的应用
CN112961338A (zh) 一种pH敏感的普朗尼克交联剂、制备方法与应用
CN120053673B (zh) 纳米前药及其制备方法和用途
KR20120120712A (ko) 헤파린-도세탁셀-토로콜산 접합체로 이루어진 표적성이 향상된 수용성 항암제 및 그의 제조방법
CN102716088A (zh) 叶酸偶联壳聚糖川芎嗪纳米粒制剂
CN121943880A (zh) 一种抗肿瘤小分子组合物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant